These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 2587812

  • 1. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.
    Cole S, Robbins L.
    Radiother Oncol; 1989 Nov; 16(3):235-43. PubMed ID: 2587812
    [Abstract] [Full Text] [Related]

  • 2. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
    Stratford IJ, Adams GE, Godden J, Howells N.
    Int J Radiat Biol; 1989 Mar; 55(3):411-22. PubMed ID: 2564037
    [Abstract] [Full Text] [Related]

  • 3. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
    Cole S, Stratford IJ, Adams GE.
    Int J Radiat Biol; 1989 Nov; 56(5):587-91. PubMed ID: 2573651
    [No Abstract] [Full Text] [Related]

  • 4. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Chaplin DJ.
    Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
    [Abstract] [Full Text] [Related]

  • 5. Bioreductive drugs and the selective induction of tumour hypoxia.
    Bremner JC, Stratford IJ, Bowler J, Adams GE.
    Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
    [Abstract] [Full Text] [Related]

  • 6. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
    Chaplin DJ, Acker B.
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):579-85. PubMed ID: 3558048
    [Abstract] [Full Text] [Related]

  • 7. Partial hypoxia as a cause of radioresistance in a human tumor xenograft: its influence illustrated by the sensitizing effect of misonidazole and hyperbaric oxygen.
    Reynaud-Bougnoux A, Lespinasse F, Malaise EP, Guichard M.
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1283-6. PubMed ID: 3759547
    [Abstract] [Full Text] [Related]

  • 8. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 9. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
    Siemann DW.
    Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
    [Abstract] [Full Text] [Related]

  • 10. The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts.
    Guichard M, Lespinasse F, Trotter M, Durand R, Chaplin D.
    Radiother Oncol; 1991 Feb; 20(2):117-23. PubMed ID: 2031087
    [Abstract] [Full Text] [Related]

  • 11. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW.
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [Abstract] [Full Text] [Related]

  • 12. Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.
    Fujimoto S, Kobayashi K, Takahashi M, Konno C, Kokubun M, Ohta M, Shrestha RD, Kiuchi S.
    Br J Cancer; 1992 Jan; 65(1):33-6. PubMed ID: 1733439
    [Abstract] [Full Text] [Related]

  • 13. Response of an experimental mammary carcinoma to fractionated X-irradiation with misonidazole and microwave hyperthermia.
    Goldfeder A, Brown DM.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1287-91. PubMed ID: 6469752
    [Abstract] [Full Text] [Related]

  • 14. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP, Gulyas S, Whitmore GF.
    Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
    [Abstract] [Full Text] [Related]

  • 15. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
    Schütze C, Bergmann R, Brüchner K, Mosch B, Yaromina A, Zips D, Hessel F, Krause M, Thames H, Kotzerke J, Steinbach J, Baumann M, Beuthien-Baumann B.
    Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
    [Abstract] [Full Text] [Related]

  • 16. BW12C: effects on tumour hypoxia, tumour thermosensitivity and relative tumour and normal tissue perfusion in C3H mice.
    Honess DJ, Hu DE, Bleehen NM.
    Br J Cancer; 1991 Oct; 64(4):715-22. PubMed ID: 1911220
    [Abstract] [Full Text] [Related]

  • 17. The effect of BW12C on the radiosensitivity and necrosis of murine tissues and tumours.
    Stevens G, Hill SA, Joiner MC, Joiner B, Johns H, Williams K, Denekamp J, Nethersell AB.
    Australas Radiol; 1994 Aug; 38(3):199-203. PubMed ID: 7945114
    [Abstract] [Full Text] [Related]

  • 18. Protection of pig epidermis against radiation-induced damage by the infusion of BW12C.
    van den Aardweg GJ, Hopewell JW, Adams GE, Barnes DW, Sansom JM, Stratford IJ, Nethersell AB.
    Int J Radiat Biol; 1991 Apr; 59(4):1039-51. PubMed ID: 1674270
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
    Wong KH, Koch CJ, Wallen CA, Wheeler KT.
    Br J Cancer; 1991 Apr; 63(4):484-8. PubMed ID: 2021530
    [Abstract] [Full Text] [Related]

  • 20. BW12C perturbs normal and tumour tissue oxygenation and blood flow in man.
    Falk SJ, Ramsay JR, Ward R, Miles K, Dixon AK, Bleehen NM.
    Radiother Oncol; 1994 Sep; 32(3):210-7. PubMed ID: 7816940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.